Keros Therapeutics, Inc.

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC KROS

Report date

12/31/2025

Quarter

2025 Q4

Filed

2/13/2026

Shares

234

Value ($000)

5

Weight

0.0%

2020 Q4 - 2025 Q4 (16 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2025 Q4	2/13/2026	5	0.0%	234	12/31/2025
2024 Q4	2/14/2025	1,020	0.0%	64,416	12/31/2024
2024 Q3	11/14/2024	2,936	0.0%	50,552	9/30/2024
2024 Q2	8/14/2024	2,206	0.0%	48,281	6/30/2024
2024 Q1	5/15/2024	1,134	0.0%	17,135	3/31/2024
2023 Q4	2/14/2024	681	0.0%	17,135	12/31/2023
2023 Q3	11/13/2023	353	0.0%	11,085	9/30/2023
2023 Q2	8/11/2023	732	0.0%	17,135	6/30/2023
2023 Q1	5/15/2023	732	0.0%	17,135	3/31/2023
2022 Q4	2/14/2023	823	0.0%	17,135	12/31/2022
2022 Q3	11/14/2022	645	0.0%	17,135	9/30/2022
2022 Q2	8/12/2022	306	0.0%	11,085	6/30/2022
2022 Q1	5/16/2022	436	0.0%	8,010	3/31/2022
2021 Q4	2/14/2022	469	0.0%	8,010	12/31/2021
2021 Q1	5/14/2021	431	0.0%	7,000	3/31/2021
2020 Q4	3/1/2021	430	0.0%	6,100	12/31/2020